Every Form 4 that Praxis Precision Medicines, Inc. (PRAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRAX filings page.
Praxis Precision Medicines, Inc. Chief Executive Officer Marcio Souza reported gifting a total of 23,121 shares of Praxis common stock. The transactions are coded as bona fide gifts, meaning they were transfers without payment rather than market sales.
The filing shows 2,600 shares previously held indirectly through his spouse were gifted to the Souza 2026 Trust, reducing that indirect position to zero. An additional 20,521 directly held shares were also gifted, leaving Souza with 56,495 Praxis shares held directly after the transactions.
Praxis Precision Medicines director Jill DeSimone reported a series of option-related trades in the company’s common stock. On June 24, 2026, she exercised options for a total of 11,600 shares at exercise prices of $44.25 and $147.30 per share, then sold 11,600 shares in multiple open-market transactions at weighted-average prices in the low $300s under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 2,337 Praxis common shares.
Praxis Precision Medicines director Stuart A. Arbuckle reported equity compensation awards. He received 1,371 restricted stock units, each representing a contingent right to one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He was also granted options to purchase 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these awards, he directly holds 2,537 common shares and 648 stock options, reflecting routine director compensation rather than open-market buying.
Praxis Precision Medicines director Jeffrey Chodakewitz received new equity awards as part of his compensation. He was granted 1,371 restricted stock units, each representing the right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He also received options for 648 shares at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 and expiring on June 10, 2036. These are awards from the company, not open-market purchases or sales.
Praxis Precision Medicines director William D. Young received new equity awards. On June 10, 2026, he was granted 1,371 restricted stock units, each representing one future share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the 2027 annual stockholders meeting.
He was also granted a stock option for 648 shares of common stock at an exercise price of $240.6600 per share, vesting in twelve equal monthly installments beginning July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting. Following these awards, he directly owns 3,269 common shares and holds options for 648 shares.
Praxis Precision Medicines director Jill DeSimone received new equity awards as part of her compensation. She was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholders meeting.
She also received a stock option for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these grants, she directly holds 2,337 shares of common stock and 648 stock options.
Praxis Precision Medicines director Merit Ester Cudkowicz reported equity compensation awards. She received 1,371 restricted stock units, each representing one future share of common stock. These units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting and are settled only in shares.
She was also granted an option to buy 648 shares of common stock at an exercise price of $240.66 per share. The option vests in 12 equal monthly installments beginning July 10, 2026, with final vesting on the earlier of June 10, 2027 or the 2027 annual meeting. Following these grants, she reports 1,371 common shares and 648 options as directly owned.
Praxis Precision Medicines director J. Dean Mitchell received equity awards as part of his compensation. He was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the 2027 annual stockholder meeting.
Mitchell was also granted stock options for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. Following these awards, he directly holds 18,622 common shares.
Praxis Precision Medicines director Jeffrey B. Kindler reported equity awards consisting of restricted stock units and stock options. He was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, bringing his reported common stock holdings to 2,537 shares after the award.
These restricted stock units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting and will be settled in shares. Kindler was also granted options for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting. The filing reflects routine director compensation grants rather than open‑market buying or selling.
Praxis Precision Medicines director Gregory Norden reported equity awards consisting of restricted stock units and stock options. He was granted 1,371 restricted stock units, each representing a contingent right to receive one share of common stock. These units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting.
In a separate award, Norden received options to buy 648 shares of common stock at an exercise price of $240.66 per share. These options vest in twelve equal monthly installments starting on July 10, 2026, with the final installment on the earlier of June 10, 2027 or the 2027 annual meeting. Following the reported grants, he holds 1,559 common shares directly and 648 options, reflecting routine director compensation rather than open-market trading.
Praxis Precision Medicines principal accounting officer Lauren Mastrocola reported an acquisition of company stock through an employee plan. On this Form 4, she acquired 127 shares of Praxis Precision Medicines, Inc. common stock at $167.943 per share. These shares were purchased under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, she directly holds a total of 13,572.656 common shares.
Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an acquisition of company stock through an employee plan. On this Form 4, Nemiroff received 78 shares of Praxis Precision Medicines common stock at a price of $167.943 per share.
These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, Nemiroff directly holds a total of 26,010.667 shares of common stock.
Praxis Precision Medicines Chief Financial Officer acquires additional shares through an employee plan. Timothy Edwin Kelly acquired 121 shares of Praxis Precision Medicines common stock at $167.943 per share on May 14, 2026 under the company’s Employee Stock Purchase Plan. Following this award, he directly holds 31,167 common shares.
Praxis Precision Medicines Chief Operating Officer acquires shares through employee plan. Megan Sniecinski acquired 89 shares of Praxis Precision Medicines common stock at an effective price of $167.943 per share under the company’s Employee Stock Purchase Plan. Following this acquisition, she directly holds 28,664 common shares.
Praxis Precision Medicines CEO Marcio Souza reported a routine compensation-related stock acquisition. On May 14, 2026, he acquired 126 shares of Common Stock at $167.943 per share under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this grant, he directly owns 77,016 shares of Praxis common stock and has an additional 2,600 shares held indirectly through his spouse.
Praxis Precision Medicines director Stuart A. Arbuckle reported new equity awards in the company. On February 6, 2026, he received 688 restricted stock units and 478 restricted stock units, each at a price of $0, with vesting tied to 2026 and 2027 service and the 2026 annual meeting. Each unit represents one share of common stock, settled only in shares. He was also granted a stock option for 224 shares at an exercise price of $319.57, vesting in monthly installments from February 26, 2026 until the earlier of June 26, 2026 or the 2026 annual meeting. Following these grants, he beneficially owns 1,166 shares of common stock and 224 stock options, all held directly.
Praxis Precision Medicines director Jeffrey B. Kindler reported new equity awards. On February 6, 2026, he received 688 restricted stock units that vest in two equal annual installments on the first two anniversaries of January 8, 2026.
He was also granted 478 restricted stock units that vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual shareholder meeting. Following these grants, he directly holds 1,166 shares of common stock tied to these awards.
In addition, Kindler received a stock option for 224 shares of common stock with a stated exercise price of $319.57 per share, vesting in equal monthly installments from February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.
Praxis Precision Medicines, Inc. reported an insider tax-withholding transaction by its Principal Accounting Officer, Lauren Mastrocola. On 01/12/2026, 344 shares of common stock were withheld by the company at a price of $275.74 per share to cover tax obligations arising from the vesting of previously reported restricted stock units. After this automatic withholding, Mastrocola directly beneficially owns 13,445.656 shares of Praxis common stock. The filing is a routine Form 4 disclosure of this non-open-market transaction.
Praxis Precision Medicines Chief Operating Officer Megan Sniecinski reported an automatic withholding of 885 shares of common stock on January 12, 2026. The issuer retained these shares to satisfy tax withholding obligations that arose when previously reported restricted stock units vested, rather than through an open-market sale.
After this tax-related withholding, Sniecinski beneficially owns 28,530 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines officer reports tax-related share withholding. General Counsel and Secretary Alex Nemiroff reported that on 01/12/2026, 768 shares of Praxis Precision Medicines common stock were withheld by the company at a price of $275.74 per share. According to the footnote, these shares were withheld by the issuer to cover tax obligations arising from the vesting of previously reported restricted stock units, rather than sold in an open-market transaction. After this withholding, Nemiroff directly beneficially owns 25,932.667 shares of Praxis common stock.
Praxis Precision Medicines, Inc. chief financial officer Kelly Timothy Edwin reported a Form 4 transaction involving company common stock. On January 12, 2026, 943 shares of Praxis common stock were withheld by the issuer at a price of $275.74 per share to cover tax withholding obligations tied to the vesting of previously reported restricted stock units. After this tax-related withholding, Edwin beneficially owned 31,046 shares of Praxis common stock in direct ownership.
Praxis Precision Medicines, Inc. reported insider equity transactions by Principal Accounting Officer Lauren Mastrocola. On January 8, 2026, she received 3,750 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. She was also granted a stock option for 7,500 shares of common stock at an exercise price of $294.38 per share, vesting over four years with 25% on January 8, 2027 and the remainder in 36 monthly installments. On January 10, 2026, 367 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations related to vesting of previously reported restricted stock units, leaving her with 13,789.656 shares of common stock held directly.
Praxis Precision Medicines, Inc. (PRAX) Chief Operating Officer Megan Sniecinski reported new equity awards and a tax-related share withholding. On January 8, 2026, she was granted 9,625 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. Also on that date, she received a stock option for 7,700 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 monthly installments.
On January 10, 2026, 1,087 shares of common stock were withheld at a price of $288.45 per share to cover tax obligations tied to previously reported restricted stock unit vesting. After these transactions, she directly held 29,415 shares of common stock and 7,700 stock options.
Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.
On the same date, he also received a stock option for 5,500 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 917 common shares were withheld at $288.45 per share to cover tax obligations from previously reported RSU vesting, leaving 26,700.667 common shares held directly and 5,500 options outstanding.
Praxis Precision Medicines’ Chief Financial Officer Timothy Edwin Kelly reported new equity awards and a tax-related share withholding. On January 8, 2026, he received 8,800 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. That same day he was granted a stock option for 7,040 shares at an exercise price of $294.38 per share, vesting 25% on January 8, 2027 and the remaining 75% in 36 monthly installments, subject to continued service. On January 10, 2026, 1,335 shares of common stock were withheld at $288.45 per share to cover tax obligations tied to earlier RSU vesting. After these transactions, he directly beneficially owned 31,989 common shares and 7,040 stock options.
Praxis Precision Medicines, Inc. Chief Executive Officer and director Marcio Souza reported new equity awards and related share activity. On January 8, 2026, he was awarded 27,640 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on January 8, 2026. That same day, he received a stock option for 22,110 shares of common stock at an exercise price of $294.38, vesting 25% on January 8, 2027 and the remaining 75% in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 4,252 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations on previously reported RSU vesting. After these transactions, he directly beneficially owned 76,890 shares of common stock, 22,110 stock options, and indirectly held 2,600 shares through his spouse.
Praxis Precision Medicines, Inc. reported an insider equity transaction by its Principal Accounting Officer, Lauren Mastrocola. On January 7, 2026, 35 shares of Praxis common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding, Mastrocola beneficially owns 10,406.656 shares of Praxis common stock directly.
Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an automatic share withholding related to equity compensation. On January 7, 2026, 89 shares of common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding event, Nemiroff beneficially owned 20,742.667 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines, Inc. reported an insider equity transaction by its Chief Financial Officer, Kelly Timothy Edwin. On 01/07/2026, 139 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units. Following this tax-related withholding, the officer directly beneficially owned 24,524 shares of Praxis common stock.
Praxis Precision Medicines Chief Executive Officer Marcio Souza reported an automatic share disposition related to tax withholding. On January 7, 2026, 405 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax obligations tied to the vesting of previously reported restricted stock units. This was not an open-market sale. After this transaction, Souza beneficially owned 53,502 common shares directly and an additional 2,600 common shares indirectly, which are held by his spouse.
Praxis Precision Medicines Chief Financial Officer reports stock purchase under employee plan
The Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing the acquisition of company stock through the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan. On 11/14/2025, the officer acquired 384 shares of common stock at a price of $31.62 per share in a transaction reported as an acquisition. Following this transaction, the officer beneficially owns 24,663 shares of Praxis common stock directly. The filing notes that the purchase was made under an employee stock purchase plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c), which govern certain insider transactions for reporting and short-swing profit rules.
Praxis Precision Medicines (PRAX) insider filing: the company’s General Counsel and Secretary reported multiple stock option exercises and related share sales on 11/20/2025. The officer exercised options to acquire blocks of common stock at exercise prices of $44.4, $56.94, $83.85 and $133.65, then sold shares in several transactions, including 1,714 shares at a weighted average price of $190.863, 13,339 shares at $192.533, 977 shares at $193.233 and 9,100 shares at $194.3. After these transactions, the reporting person directly owned 20,831.667 shares of Praxis common stock, along with remaining stock options over additional shares that vest over time. The filing notes that the transactions were effected for estate planning purposes.
Praxis Precision Medicines (PRAX) reported insider activity by its Principal Accounting Officer on a Form 4. On 11/20/2025, the officer exercised multiple stock options, acquiring Praxis common stock at exercise prices of $49.5, $83.85, $133.65, $43.37, $44.4, and $56.94 per share. The same day, the officer sold 11,455 shares at a weighted average price of $191.958 and 2,145 shares at a weighted average price of $192.711, in multiple transactions within narrow price ranges. After these transactions, the officer beneficially owned 10,441.656 shares of Praxis common stock directly. The filing notes that the transactions were effected for estate planning purposes, and several option grants referenced were already fully vested or continue to vest over time.
Praxis Precision Medicines (PRAX): insider transaction reported. Affiliated entities of Adage Capital reported multiple open‑market sales of Common Stock on 10/16/2025 across several tranches at weighted‑average prices ranging from $90.0025 to $140.0000. One disclosed tranche was 250,000 shares at $104.3095.
Following these sales, the reporting persons beneficially owned 2,060,175 PRAX shares indirectly. The securities are held by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager; Robert Atchinson and Phillip Gross are managing members of related general partners. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Mitchell Dean J, a director of Praxis Precision Medicines, Inc. (PRAX), reported multiple option exercises and resulting share holdings on 09/24/2025. He acquired 1,932 shares via exercise at $14.36, 8,566 shares at $44.25 and 1,753 shares at $44.04, increasing his direct beneficial ownership to 17,251 shares. The related options have varying vesting histories: the $14.36 option fully vested 06/12/2024, the $44.25 option fully vested 06/05/2025, and the $44.04 option vests monthly over one year starting 06/26/2025. The reported transactions were filed by an attorney-in-fact on 09/25/2025.